Scope and Impact of the Recall
Teva Pharmaceuticals USA initiated the voluntary recall on October 7, 2025, with Amerisource Health Services following suit on October 26. In total, nearly 590,000 bottles across 55 separate lots are affected. The recalled bottles contain between 100 and 1,000 capsules each, with specific quantities for each strength: 181,659 bottles of 1 mg, 291,512 bottles of 2 mg, and 107,673 bottles of 5 mg.
Prazosin hydrochloride is a crucial medication used to relax blood vessels and lower blood pressure, thereby helping to prevent strokes, heart attacks, and kidney failure. It is also sometimes prescribed off-label to manage nightmares and sleep disturbances associated with post-traumatic stress disorder (PTSD).
Guidance for Patients and Healthcare Providers
